Biocon Ltd Share Price
As on 22 November 2025 at 10:17 IST
Biocon Q1 FY26 Results:
Net profit declined 90% to ₹89 crores, compared to ₹862 crores in Q1 FY25. Total income in Q1 FY26 declined 12% to ₹4,022 crores from ₹4,567 crores in the same period last year.
About Biocon Ltd
Biocon Ltd. was established in 1978 and is a leading biopharmaceutical company. It was established by Kiran Mazumdar-Shaw in 1978. With decades of experience, Biocon has made strides in developing and manufacturing affordable biosimilars. The headquarters of the company is located in Bengaluru, Karnataka, India. Biocon operates in the biopharmaceutical sector, and has carved out a niche for itself with its innovative products. The company’s main offerings include biosimilars such as Insugen, Basalog, and CANMAb. Along with that, they also provide generic formulations and novel biologics. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
8.47%
Over 6 Months
18.84%
Over 1 Year
22.30%
Over 3 Years
38.43%
Biocon Ltd Summary
Close ₹395.15
Open ₹407.90
High ₹407.90
Low ₹391.30
Volume 84,63,319
Net Turnover (in Cr) ₹334.96
52Wk High ₹424.95
52Wk Low ₹291
52Wk High / Low
291
424.95
Biocon Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹52,830.12
EPS (TTM) 0.60
Book Value (BV) 119.54
Div. Yield 0.11 %
P/E (TTM) 79.21
Price/Book Value 3.31
Delivery % 39.55 %
Face Value 5
Key Ratios
PE Ratio 67.30
PB Ratio 3.55
EV to Sales 19.44
PEG Ratio 0.16
ROA 4.20
ROE 0.40
Debt-Equity 0.22
Net Profit Margin 2
Operating Profit Margin 18.43
Biocon Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 16,469.90 | 15,621.20 | 11,550.10 | 8,396.70 | 7,397.60 |
| Total Expenses | 14,679.80 | 14,000.20 | 10,194.60 | 7,095.60 | 6,263.10 |
| Profit Before Tax | 1,886.60 | 1,525.20 | 897.10 | 983.10 | 1,067.70 |
| Profit After Tax | 1,429.40 | 1,297.80 | 643 | 771.60 | 846.20 |
| Operating Profit After Depreciation | 2,687.50 | 2,595.40 | 1,774.50 | 1,368.70 | 1,192.20 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 36,370 | 34,651.70 | 34,197.20 | 7,259.10 | 6,910.60 |
| Total Non Current Assets | 42,511.10 | 40,891.50 | 39,708.80 | 12,011.70 | 10,921.90 |
| Total Current Assets | 16,286.20 | 15,179.20 | 12,334 | 8,382.30 | 7,600.40 |
| Total Assets | 58,797.30 | 56,070.70 | 52,042.80 | 20,394 | 18,522.30 |
| Total Shareholder's Fund | 21,644 | 19,783.70 | 17,866.90 | 8,432.50 | 7,626.90 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 4,061.20 | 2,953.90 | 1,852.50 | 1,176.60 | 1,159.70 |
| Net Cash Used In Investing Activities | -202.90 | -1,001.60 | -14,260.10 | -1,662 | -3,651.40 |
| Net Cash Used In Financing Activities | -1,854 | -2,332.70 | 13,048.70 | 242.10 | 2,564 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Total Revenue | 2,484.90 | 2,320.30 | 2,264.30 | 1,925.40 | 2,178.60 |
| Total Expenses | 2,431.50 | 2,184.50 | 2,155.90 | 1,785.70 | 1,819.80 |
| Profit Before Tax | 660.90 | 150.30 | 2,971.20 | 139.70 | 358.80 |
| Profit After Tax | 609.30 | 119.30 | 2,848.40 | 86.10 | 280.50 |
| Operating Profit After Depreciation | 290.30 | 334.60 | 178 | 140.10 | 359.20 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Fixed Assets | 1,074.10 | 915 | 914 | 819.30 | 743.20 |
| Total Non Current Assets | 13,450.90 | 11,008.20 | 10,463.90 | 6,466.80 | 6,404.40 |
| Total Current Assets | 2,170.20 | 2,760 | 2,566 | 2,402.20 | 2,169.30 |
| Total Assets | 15,621.10 | 13,768.20 | 13,029.90 | 8,869 | 8,573.70 |
| Total Shareholder's Fund | 11,524.40 | 10,912.30 | 10,916 | 8,092.90 | 7,907.10 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 623.90 | -123.20 | 219.30 | 47.60 | 478.40 |
| Net Cash Used In Investing Activities | -991.50 | -294.70 | -1,173.10 | -302.10 | -627.70 |
| Net Cash Used In Financing Activities | 494.80 | 343.60 | 1,039.40 | 112 | 27.80 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 4,295.50 | 3,941.90 | 4,417 | 3,821.40 | 3,590.40 |
| Total Expenses | 3,460.10 | 3,193 | 3,338.80 | 3,069.60 | 2,905 |
| Profit Before Tax | 171.30 | 96.90 | 486.80 | 155.90 | 98.40 |
| Profit After Tax | 132.80 | 89.20 | 459.40 | 81.10 | 27.10 |
| Operating Profit after Depreciation | 928.40 | 828.60 | 1,115.10 | 786.60 | 717.90 |
| Particulars (in ₹ Cr.) | 2025-09 | 2025-06 | 2025-03 | 2024-12 | 2024-09 |
|---|---|---|---|---|---|
| Total Revenue | 583.30 | 537.10 | 643.80 | 562.80 | 525.40 |
| Total Expenses | 530.40 | 516.50 | 581.80 | 531.50 | 487.80 |
| Profit Before Tax | 85.70 | -7.60 | 35 | 603.90 | 20.90 |
| Profit After Tax | 70.90 | -8.30 | 21.20 | 584 | 3.20 |
| Operating Profit after Depreciation | 186.70 | 81.90 | 124.70 | 95.50 | 111.10 |
Biocon Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 388.33
S2 381.52
S3 371.73
Pivot 398.12
R1 404.93
R2 414.72
R3 421.53
Moving Average
20 SMA 387.14
50 SMA 368.39
100 SMA 369.83
200 SMA 354.33
Biocon Ltd Corporate Actions
Biocon Ltd
₹0.5/Share
Announcement Date 04 Jul 2025
Record Date 04 Jul 2025
Div Yield 10%
Biocon Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,777.85 | ₹4,26,565.77 |
| Divis Laboratories Ltd | ₹6,463.80 | ₹1,71,593.58 |
| Torrent Pharmaceuticals Ltd | ₹3,717.75 | ₹1,25,819.90 |
| Cipla Ltd | ₹1,528.95 | ₹1,23,504.18 |
| Dr Reddys Laboratories Ltd | ₹1,247.65 | ₹1,04,131.51 |
Biocon Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| ICICI Pru P.H.D Fund | 3.28% |
| Nippon India Focused Fund | 3.12% |
| SBI Midcap Fund | 2.26% |
| SBI Contra Fund | 2.18% |
| Franklin India Mid Cap Fund | 1.71% |
Biocon Ltd News
Biocon drops after brokerage downgrades stock to 'Sell'
Biocon tumbled 3.32% to Rs 396.25 after a foreign brokerage issued a double downgrade on the stock, cutting its rating to Sell from Buy and slashing its target price.
20 Nov 2025, 02:27 pm
Biocon Ltd spurts 1.95%, up for third straight session
Biocon Ltd is quoting at Rs 392.6, up 1.95% on the day as on 12:49 IST on the NSE. The stock is up 18.41% in last one year as compared to a 9.99% gain in NIFTY and a 3.35% gain in the Nifty Pharma index.
12 Nov 2025, 01:05 pm
Biocon Ltd up for third consecutive session
Biocon Ltd is quoting at Rs 385.15, up 1.22% on the day as on 12:49 IST on the NSE. The stock is up 17.42% in last one year as compared to a 5.78% gain in NIFTY and a 0.93% gain in the Nifty Pharma index.
06 Nov 2025, 01:05 pm
Biocon's biologics arm gets Health Canada approval for monoclonal antibody drug Yesintek
Biocon said that Health Canada has granted a notice of compliance (NOC) for Yesintek and Yesintek I.V. to Biocon Biologics.
23 Oct 2025, 12:58 pm
Biocon Biologics expands its strategic collaboration with Civica
To include Insulin Glargine medicine for commercialization in the US market
16 Oct 2025, 04:28 pm
Biocon Ltd Stock Analysis
- Annual revenue for Biocon Ltd increased by 7.09% to ₹2,484.90 crore in FY 2025 from ₹2,320.30 crore in FY 2024.
- Annual Net Profit for Biocon Ltd increased by 410.73% to ₹609.30 crore in FY 2025 from ₹119.30 crore in FY 2024.
- Promoter Shareholding in Biocon Ltd remains unchanged by 0.00% in the most recent quarter, from 54.45% in June 2025 to 54.45% in September 2025.
- Biocon Ltd delivered a 1-year return of 22.30% compared to the Nifty 50, which provided a return of 12.17% as of the last trading session.
- Biocon Ltd share price moved up by 1.27% from its previous close of INR ₹395.15. The latest Biocon Ltd share price is INR ₹400.15.
- Biocon Ltd share price today has been at a low of 395.45 and a high of 401.20. Over the past 52 weeks, the Biocon Ltd share price has seen a low of 291 and a high of 424.95.
About Biocon Ltd
Biocon Ltd. was established in 1978. It is a leading biopharmaceutical company headquartered in Bengaluru, Karnataka, India. With many decades of experience, Biocon has made strides in developing and manufacturing affordable biosimilars. This also goes for generic formulations, and complex APIs (Active Pharmaceutical Ingredients). The company also offers research services and social initiatives focused on healthcare and education.
Operating in the biopharmaceutical sector, Biocon has carved out a niche for itself with its innovative products. The company’s main offerings include biosimilars such as Insugen, Basalog, and CANMAb. Along with that, they provide generic formulations and novel biologics. These products have helped Biocon establish a strong presence both in India and globally.
Kiran Mazumdar-Shaw is the founder and Executive Chairperson. He has been a driving force behind Biocon’s success. Under her leadership, the company has become one of India’s largest biopharmaceutical firms. However, it is not stated as the biggest player in the industry. The promoter shareholding is Kiran Mazumdar-Shaw. She holds a substantial stake in the company. She holds a 60.64% stake in the company. Biocon’s registered office is located at 20th KM, Hosur Road, Electronic City, Bengaluru - 560 100, Karnataka, India. The company’s registrar is KFin Technologies Limited. Key management promoters include:
Innovative Product Development Biocon’s commitment to innovation is evident in its diverse product portfolio. This includes biosimilars like Insugen, Basalog, and CANMAb. It also includes novel biologics and generic formulations. These products have enhanced Biocon’s market presence. It has provided cost-effective treatment options for chronic diseases such as diabetes and autoimmune disorders. The company’s focus on biosimilars has positioned it as a key player in the biopharmaceutical sector. It is addressing the growing demand for affordable biologic therapies.
Global Reach and Collaborations Biocon’s impact extends beyond India, with a significant presence in global markets. The company has established strategic partnerships and collaborations with leading pharmaceutical companies worldwide. It is enhancing its research capabilities and market reach. For instance, Biocon’s collaboration with Mylan has been developing and commercializing biosimilars in international markets. Additionally, Biocon has a licensing agreement with Tabuk Pharmaceutical Manufacturing Company. This was to market its GLP-1 products in the Middle East. This exemplifies its strategic expansion efforts.
Research and Development Investment in research and development (R&D) is a cornerstone of Biocon’s strategy. The company has allocated many resources to R&D. It focuses on novel biologics and innovative therapies. This commitment has led to the development of cutting-edge treatments. It has positioned Biocon as a leader in biopharmaceutical innovation.
Regulatory Milestones Biocon’s adherence to stringent regulatory standards has been pivotal in its success. The company’s facilities undergo regular inspections. Global regulatory authorities, including the US FDA do this. Recently, Biocon’s API facility in Bengaluru received four observations from the US FDA. The company is addressing this within the stipulated timeframe. Such regulatory scrutiny ensures that Biocon’s products meet the highest quality standards. It is reinforcing its reputation as a reliable biopharmaceutical manufacturer.
Sustainability and Social Responsibility Sustainable development is integral to Biocon’s business strategy. The company is committed to creating social and ecological impacts through various initiatives. Biocon’s sustainability efforts include reducing its carbon footprint. It also includes conserving water and promoting renewable energy. Additionally, the Biocon Foundation undertakes numerous healthcare and education initiatives. It is improving the quality of life for underserved communities. These efforts underscore Biocon’s dedication to being a responsible corporate citizen.
Economic Impact Biocon’s economic contributions are large, generating significant revenue and employment opportunities. Its market reflects its strong financial performance and investor confidence. Strategic acquisitions, product launches, and market expansions have marked the company’s growth. These are contributing to its robust economic footprint.
Challenges and Future Outlook Despite its successes, Biocon faces challenges such as regulatory hurdles. It faces market competition and the need for continuous innovation. Addressing these challenges requires sustained investment in R&D. It also requires adherence to regulatory standards and strategic market positioning. Looking ahead, Biocon aims to expand its biosimilar portfolio and enhance its global presence. It will continue its focus on affordable healthcare solutions.
Biocon Ltd.’s impact on the biopharmaceutical industry is profound. Global collaborations and commitment to sustainability drive it. The company’s efforts have advanced healthcare. It has contributed to economic growth and social well-being. Biocon continues to steer the complexities of the biopharmaceutical landscape. Its focus on innovation and affordability will remain central to its mission of transforming global healthcare.
Operating in the biopharmaceutical sector, Biocon has carved out a niche for itself with its innovative products. The company’s main offerings include biosimilars such as Insugen, Basalog, and CANMAb. Along with that, they provide generic formulations and novel biologics. These products have helped Biocon establish a strong presence both in India and globally.
Kiran Mazumdar-Shaw is the founder and Executive Chairperson. He has been a driving force behind Biocon’s success. Under her leadership, the company has become one of India’s largest biopharmaceutical firms. However, it is not stated as the biggest player in the industry. The promoter shareholding is Kiran Mazumdar-Shaw. She holds a substantial stake in the company. She holds a 60.64% stake in the company. Biocon’s registered office is located at 20th KM, Hosur Road, Electronic City, Bengaluru - 560 100, Karnataka, India. The company’s registrar is KFin Technologies Limited. Key management promoters include:
- Kiran Mazumdar-Shaw
- Siddharth Mittal
- Ravi Rasendra Mazumdar
- Eric Vivek Mazumdar
- Maleveetil Damodaran
Impact of the Company
Biocon Ltd. is a pioneering biopharmaceutical company based in Bengaluru, Karnataka, India. It has made significant contributions to the global healthcare landscape since its start in 1978. Over the past decades, Biocon has focused on developing affordable biosimilars. It has focused on generic formulations and complex APIs (Active Pharmaceutical Ingredients). It is making essential medicines accessible to a broader population.Innovative Product Development Biocon’s commitment to innovation is evident in its diverse product portfolio. This includes biosimilars like Insugen, Basalog, and CANMAb. It also includes novel biologics and generic formulations. These products have enhanced Biocon’s market presence. It has provided cost-effective treatment options for chronic diseases such as diabetes and autoimmune disorders. The company’s focus on biosimilars has positioned it as a key player in the biopharmaceutical sector. It is addressing the growing demand for affordable biologic therapies.
Global Reach and Collaborations Biocon’s impact extends beyond India, with a significant presence in global markets. The company has established strategic partnerships and collaborations with leading pharmaceutical companies worldwide. It is enhancing its research capabilities and market reach. For instance, Biocon’s collaboration with Mylan has been developing and commercializing biosimilars in international markets. Additionally, Biocon has a licensing agreement with Tabuk Pharmaceutical Manufacturing Company. This was to market its GLP-1 products in the Middle East. This exemplifies its strategic expansion efforts.
Research and Development Investment in research and development (R&D) is a cornerstone of Biocon’s strategy. The company has allocated many resources to R&D. It focuses on novel biologics and innovative therapies. This commitment has led to the development of cutting-edge treatments. It has positioned Biocon as a leader in biopharmaceutical innovation.
Regulatory Milestones Biocon’s adherence to stringent regulatory standards has been pivotal in its success. The company’s facilities undergo regular inspections. Global regulatory authorities, including the US FDA do this. Recently, Biocon’s API facility in Bengaluru received four observations from the US FDA. The company is addressing this within the stipulated timeframe. Such regulatory scrutiny ensures that Biocon’s products meet the highest quality standards. It is reinforcing its reputation as a reliable biopharmaceutical manufacturer.
Sustainability and Social Responsibility Sustainable development is integral to Biocon’s business strategy. The company is committed to creating social and ecological impacts through various initiatives. Biocon’s sustainability efforts include reducing its carbon footprint. It also includes conserving water and promoting renewable energy. Additionally, the Biocon Foundation undertakes numerous healthcare and education initiatives. It is improving the quality of life for underserved communities. These efforts underscore Biocon’s dedication to being a responsible corporate citizen.
Economic Impact Biocon’s economic contributions are large, generating significant revenue and employment opportunities. Its market reflects its strong financial performance and investor confidence. Strategic acquisitions, product launches, and market expansions have marked the company’s growth. These are contributing to its robust economic footprint.
Challenges and Future Outlook Despite its successes, Biocon faces challenges such as regulatory hurdles. It faces market competition and the need for continuous innovation. Addressing these challenges requires sustained investment in R&D. It also requires adherence to regulatory standards and strategic market positioning. Looking ahead, Biocon aims to expand its biosimilar portfolio and enhance its global presence. It will continue its focus on affordable healthcare solutions.
Biocon Ltd.’s impact on the biopharmaceutical industry is profound. Global collaborations and commitment to sustainability drive it. The company’s efforts have advanced healthcare. It has contributed to economic growth and social well-being. Biocon continues to steer the complexities of the biopharmaceutical landscape. Its focus on innovation and affordability will remain central to its mission of transforming global healthcare.
FAQ’s
What is the share price of Biocon Ltd today?
Biocon Ltd share price as on 22 Nov 2025 is ₹ 400.15
What is the Market Cap of Biocon Ltd?
The market cap of Biocon Ltd stock is ₹52,830.12 Cr.
What is the PE Ratio of Biocon Ltd?
The Price to Earnings (P/E) Ratio of Biocon Ltd is 67.30
What is the PB Ratio of Biocon Ltd?
The Price to Book (P/B) Ratio of Biocon Ltd is 3.55
What is the 52 week high of Biocon Ltd Share Price?
The 52 week high of Biocon Ltd share price stands at ₹424.95
What is the 52 week low of Biocon Ltd Share Price?
The 52 week low of Biocon Ltd share price stands at ₹291
How can I buy shares of Biocon Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Biocon Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
